|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Zhang W, Ruan X, Li Y, Zhi J, Hu L, Hou X,
Shi X, Wang X, Wang J, Ma W, et al: KDM1A promotes thyroid cancer
progression and maintains stemness through the Wnt/β-catenin
signaling pathway. Theranostics. 12:1500–1517. 2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American thyroid association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Davies L and Welch HG: Current thyroid
cancer trends in the United States. JAMA Otolaryngol Head Neck
Surg. 140:317–322. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Jiang D, Rasul A, Batool R, Sarfraz I,
Hussain G, Mateen Tahir M, Qin T, Selamoglu Z, Ali M, Li J and Li
X: Potential anticancer properties and mechanisms of action of
formononetin. Biomed Res Int. 2019(5854315)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Xin M, Wang Y, Ren Q and Guo Y:
Formononetin and metformin act synergistically to inhibit growth of
MCF-7 breast cancer cells in vitro. Biomed Pharmacother.
109:2084–2089. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chen J, Zeng J, Xin M, Huang W and Chen X:
Formononetin induces cell cycle arrest of human breast cancer cells
via IGF1/PI3K/Akt pathways in vitro and in vivo. Horm Metab Res.
43:681–686. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhou R, Xu L, Ye M, Liao M, Du H and Chen
H: Formononetin inhibits migration and invasion of MDA-MB-231 and
4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through
PI3K/AKT signaling pathways. Horm Metab Res. 46:753–760.
2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhang L, Gong Y, Wang S and Gao F:
Anti-colorectal cancer mechanisms of formononetin identified by
network pharmacological approach. Med Sci Monit. 25:7709–7714.
2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wang WS and Zhao CS: Formononetin exhibits
anticancer activity in gastric carcinoma cell and regulating
miR-542-5p. Kaohsiung J Med Sci. 37:215–225. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yang C, Xie Q, Zeng X, Tao N, Xu Y, Chen
Y, Wang J and Zhang L: Novel hybrids of podophyllotoxin and
formononetin inhibit the growth, migration and invasion of lung
cancer cells. Bioorg Chem. 85:445–454. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chan HL and Morey L: Emerging Roles for
polycomb-group proteins in stem cells and cancer. Trends Biochem
Sci. 44:688–700. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Klauke K, Radulović V, Broekhuis M,
Weersing E, Zwart E, Olthof S, Ritsema M, Bruggeman S, Wu X, Helin
K, et al: Polycomb Cbx family members mediate the balance between
haematopoietic stem cell self-renewal and differentiation. Nat Cell
Biol. 15:353–362. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Ismail IH, Gagné JP, Caron MC, McDonald D,
Xu Z, Masson JY, Poirier GG and Hendzel MJ: CBX4-mediated SUMO
modification regulates BMI1 recruitment at sites of DNA damage.
Nucleic Acids Res. 40:5497–5510. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pan Y, Li Q, Cao Z and Zhao S: The SUMO E3
ligase CBX4 is identified as a poor prognostic marker of gastric
cancer through multipronged OMIC analyses. Genes Dis. 8:827–837.
2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wang B, Tang J, Liao D, Wang G, Zhang M,
Sang Y, Cao J, Wu Y, Zhang R, Li S, et al: Chromobox homolog 4 is
correlated with prognosis and tumor cell growth in hepatocellular
carcinoma. Ann Surg Oncol. 20 (Suppl 3):S684–S692. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hu C, Zhang Q, Tang Q, Zhou H, Liu W,
Huang J, Liu Y, Wang Q, Zhang J, Zhou M, et al: CBX4 promotes the
proliferation and metastasis via regulating BMI-1 in lung cancer. J
Cell Mol Med. 24:618–631. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Fang X and Pan A: MiR-507 inhibits the
progression of gastric carcinoma via targeting CBX4-mediated
activation of Wnt/β-catenin and HIF-1α pathways. Clin Transl Oncol.
24:2021–2028. 2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Jiang N, Niu G, Pan YH, Pan W, Zhang MF,
Zhang CZ and Shen H: CBX4 transcriptionally suppresses KLF6 via
interaction with HDAC1 to exert oncogenic activities in clear cell
renal cell carcinoma. EBioMedicine. 53(102692)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wen LJ, Wang YS and Tan PY: miR-515-5p
inhibits the proliferation, migration and invasion of human breast
cancer cells by targeting CBX4. Exp Ther Med.
22(1328)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Winer A, Adams S and Mignatti P: Matrix
metalloproteinase inhibitors in cancer therapy: Turning past
failures into future successes. Mol Cancer Ther. 17:1147–1155.
2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Aiello NM and Kang Y: Context-dependent
EMT programs in cancer metastasis. J Exp Med. 216:1016–1026.
2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Paduch R: The role of lymphangiogenesis
and angiogenesis in tumor metastasis. Cell Oncol (Dordr).
39:397–410. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Khan AQ, Ahmed EI, Elareer N, Fathima H,
Prabhu KS, Siveen KS, Kulinski M, Azizi F, Dermime S, Ahmad A, et
al: Curcumin-mediated apoptotic cell death in papillary thyroid
cancer and cancer stem-like cells through targeting of the
JAK/STAT3 signaling pathway. Int J Mol Sci. 21(438)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Li W, Chen H, Wang Z, Liu J, Lei X and
Chen W: Chromobox 4 (CBX4) promotes tumor progression and stemness
via activating CDC20 in gastric cancer. J Gastrointest Oncol.
13:1058–1072. 2022.PubMed/NCBI View Article : Google Scholar
|
